Pregnancy Clinical Trial
— We2-POfficial title:
Promoting Healthy Brain Development Via Prenatal Stress Reduction: An Innovative Precision Medicine Approach: An Intervention Feasibility and Acceptability Pilot
Verified date | October 2021 |
Source | Northwestern University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The investigators are studying strategies and tools that women can use to manage stress and wellness during pregnancy. The purpose of this project is to test a technology-enhanced version of a wellness intervention for women during their pregnancy (the Mothers and Babies course; MB). The technology that the investigators will test includes wearable heart rate sensors, smartphone text message surveys, and intervention materials delivered through text message.
Status | Completed |
Enrollment | 17 |
Est. completion date | January 31, 2021 |
Est. primary completion date | January 31, 2019 |
Accepts healthy volunteers | No |
Gender | Female |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - 10-18 weeks gestation - singleton pregnancy - receiving prenatal care from a Northwestern University prenatal care clinic & planning to deliver at Northwestern Hospitals - English-speaking - must own a smartphone - must be willing to receive text messages and respond to short online surveys using their smartphone - must also agree to wear a wireless adhesive sensor daily - must have WiFi internet access for the duration of their participation in the study Exclusion Criteria: - have known chronic medical or pregnancy complications that may place their infant at risk for neurological disorders (e.g., HIV; acute cytomegalovirus infection (CMV); toxoplasmosis; zika virus; Phenylketonuria (PKU); chromosomal anomalies; metabolic disorder; substance use disorders) - have significant mental health disorders (e.g., schizophrenia, bipolar disorder, psychosis) which could interfere with study adherence - unable to wear the BioStamp Sensor due to known skin sensitivity (e.g., allergy to adhesives or silicone), current skin irritation, or broken skin at the placement site - pacemaker or other sensitive medical device - unable to provide informed consent, complete MB sessions, or complete study assessments in English - currently participating in another MB course at the time of recruitment |
Country | Name | City | State |
---|---|---|---|
United States | Northwestern University | Chicago | Illinois |
Lead Sponsor | Collaborator |
---|---|
Northwestern University | Ann & Robert H Lurie Children's Hospital of Chicago |
United States,
de Bruijn AT, van Bakel HJ, van Baar AL. Sex differences in the relation between prenatal maternal emotional complaints and child outcome. Early Hum Dev. 2009 May;85(5):319-24. doi: 10.1016/j.earlhumdev.2008.12.009. Epub 2009 Jan 21. — View Citation
Grizenko N, Fortier ME, Zadorozny C, Thakur G, Schmitz N, Duval R, Joober R. Maternal Stress during Pregnancy, ADHD Symptomatology in Children and Genotype: Gene-Environment Interaction. J Can Acad Child Adolesc Psychiatry. 2012 Feb;21(1):9-15. — View Citation
Kinsella MT, Monk C. Impact of maternal stress, depression and anxiety on fetal neurobehavioral development. Clin Obstet Gynecol. 2009 Sep;52(3):425-40. doi: 10.1097/GRF.0b013e3181b52df1. Review. — View Citation
Mendelson T, Leis JA, Perry DF, Stuart EA, Tandon SD. Impact of a preventive intervention for perinatal depression on mood regulation, social support, and coping. Arch Womens Ment Health. 2013 Jun;16(3):211-8. doi: 10.1007/s00737-013-0332-4. Epub 2013 Mar 2. — View Citation
O'Connor TG, Heron J, Golding J, Glover V; ALSPAC Study Team. Maternal antenatal anxiety and behavioural/emotional problems in children: a test of a programming hypothesis. J Child Psychol Psychiatry. 2003 Oct;44(7):1025-36. — View Citation
Talge NM, Neal C, Glover V; Early Stress, Translational Research and Prevention Science Network: Fetal and Neonatal Experience on Child and Adolescent Mental Health. Antenatal maternal stress and long-term effects on child neurodevelopment: how and why? J Child Psychol Psychiatry. 2007 Mar-Apr;48(3-4):245-61. Review. — View Citation
Tandon SD, Leis JA, Mendelson T, Perry DF, Kemp K. Six-month outcomes from a randomized controlled trial to prevent perinatal depression in low-income home visiting clients. Matern Child Health J. 2014 May;18(4):873-81. doi: 10.1007/s10995-013-1313-y. — View Citation
Tandon SD, Perry DF, Mendelson T, Kemp K, Leis JA. Preventing perinatal depression in low-income home visiting clients: a randomized controlled trial. J Consult Clin Psychol. 2011 Oct;79(5):707-12. doi: 10.1037/a0024895. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Usability/Wearability Feedback | Participants will also be asked to provide survey feedback regarding the sensor's usability and wearability, and responding to the Environmental Momentary Assessments (EMAs). | At post-intervention (approx. week 13) | |
Primary | Intervention Acceptability | All participants will complete a brief intervention rating checklist after completing each MB module (3 total). Additional acceptability information will be ascertained during the exit interview and survey at the end of the intervention to assess participants' overall ratings of the MB course, whether they would recommend the intervention to similar women, and suggestions for intervention modifications. | After each of the 12 MB sessions (approx. weekly during weeks 2-13) | |
Secondary | Intervention fidelity | MB intervention fidelity delivered by facilitators will be measured by collecting data on a) intervention session completion and b) fidelity of intervention implementation. Facilitators will completed an intervention Facilitator Fidelity Rating Form immediately at the end of each visit. The fidelity rating form will measure 1) How much of each topic was covered; 2) How well the participant understood each topic; 3) participant engagement in each topic; 4) Any challenges when discussing the topic. | After each of the 12 MB sessions (approx. weekly during weeks 2-13) | |
Secondary | Ecological Momentary Assessment Subjective Stress Ratings | In-field, self-report EMAs will measure participants' negative and positive emotion, stress, and other factors (e.g., health behaviors) that may influence sensor readings. These surveys, delivered via text message, contain 4 questions on a 5-pt Likertscale from 'not at all' to 'very much', one on a 7-pt Likert scale from 'not at all' to 'very much', six on a binary yes/no scale, six on a visual analog scale from 'not at all' to 'extremely', and four for elaboration. | Five times daily for approx. weeks 1-13, and one week per month afterward until birth | |
Secondary | Objective stress response | Investigators will continuously collect raw ECG and accelerometer data from the BioStamp Sensor. | Continuously during the intervention (approx. weeks 2-13) | |
Secondary | Perceived Stress (State Trait Anxiety Inventory) | 40 questions about stress and anxiety-related feelings on a 4-pt Likert scale from 'Almost Never' to 'Almost Always'. | Day 1, post-intervention (approx. week 13), 1 month prior to, and 1 month after delivery | |
Secondary | Perceived Stress (Life events scale distress rating) | 28 questions about the undesirability/negativity of a variety of life events that could happen to the participant or someone close to them on a 4-pt Likert scale from 'Not at all' to 'Very much'. | Day 1, post-intervention (approx. week 13), 1 month prior to, and 1 month after delivery | |
Secondary | Perceived Stress (Perceived stress scale) | 10 questions about emotions on a 5-pt Likert scale of 'Never' to 'Very Often' | Day 1, post-intervention (approx. week 13), 1 month prior to, and 1 month after delivery | |
Secondary | Depression symptoms (behavioral activation depression scale) | 25 questions about depressive feelings and behaviors on a 7-pt Likert scale from 'Not at All' to 'Completely' | Day 1, post-intervention (approx. week 13), 1 month prior to, and 1 month after delivery | |
Secondary | Perceived stress (Prenatal Distress Questionnaire) | 17 questions about feeling bothered, worried, or upset on a 3-pt Likert scale from 'Not at all' to 'Very much'; Three open-ended questions to elaborate. | Day 1, post-intervention (approx. week 13), 1 month prior to, and 1 month after delivery | |
Secondary | Depression symptoms (PROMIS depression) | 28 questions about depression-related thoughts and feelings on a 5-pt Likert scale from 'Never' to Always' | Day 1, post-intervention (approx. week 13), 1 month prior to, and 1 month after delivery | |
Secondary | Depression symptoms (negative mood regulation scale) | 30 questions about depression-related thoughts and feelings on a 5-pt Likert scale from 'Strong disagreement' to 'Strong agreement'. | Day 1, post-intervention (approx. week 13), 1 month prior to, and 1 month after delivery | |
Secondary | Depression symptoms (MOS social support survey) | 19 questions on feelings of support from others on a 5-pt Likert scale from 'None of the time' to 'All of the time'. | Day 1, post-intervention (approx. week 13), 1 month prior to, and 1 month after delivery | |
Secondary | Depression symptoms (Experiences Questionnaire) | 20 questions about thoughts and feelings on a 5-pt Likert scale from 'Never' to 'All the time'. | Day 1, post-intervention (approx. week 13), 1 month prior to, and 1 month after delivery | |
Secondary | Depression symptoms (Edinburgh depression scale) | 10 questions about negative emotions on a 4-pt Likert scale from 'No/Never' to 'Yes/A lot'. | Day 1, post-intervention (approx. week 13), 1 month prior to, and 1 month after delivery | |
Secondary | Depression symptoms (Prenatal Health Behavior Scale) | 24 questions about diet, exercise, and drug use on a 5-pt Likert scale from 'Never' to 'Very Often' | Day 1, post-intervention (approx. week 13), 1 month prior to, and 1 month after delivery | |
Secondary | Intervention skills (five facet mindfulness questionnaire) | 39 questions about mindfulness behaviors on a 5-pt Likert scale from 'Never or very rarely true' to 'Very often or always true' | Day 1, post-intervention (approx. week 13), 1 month prior to, and 1 month after delivery | |
Secondary | Intervention skills (MB skills use survey) | 35 questions about intervention skill use frequency (5-pt Likert scale from 'Every Day' to 'Not at all'), helpfulness and enjoyability (3-pt Likert scales from 'Not at all' to 'Very') | Day 1, post-intervention (approx. week 13), 1 month prior to, and 1 month after delivery |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03442582 -
Afluria Pregnancy Registry
|
||
Terminated |
NCT02161861 -
Improvement of IVF Fertilization Rates, by the Cyclic Tripeptide FEE - Prospective Randomized Study
|
N/A | |
Not yet recruiting |
NCT05934318 -
L-ArGinine to pRevent advErse prEgnancy Outcomes (AGREE)
|
N/A | |
Enrolling by invitation |
NCT05415371 -
Persistent Poverty Counties Pregnant Women With Medicaid
|
N/A | |
Completed |
NCT04548102 -
Effects of Fetal Movement Counting on Maternal and Fetal Outcome Among High Risk Pregnant Woman
|
N/A | |
Completed |
NCT03218956 -
Protein Requirement During Lactation
|
N/A | |
Completed |
NCT02191605 -
Computer-delivered Screening & Brief Intervention for Marijuana Use in Pregnancy
|
N/A | |
Completed |
NCT02223637 -
Meningococcal Quadrivalent CRM-197 Conjugate Vaccine Pregnancy Registry
|
||
Recruiting |
NCT06049953 -
Maternal And Infant Antipsychotic Study
|
||
Completed |
NCT02577536 -
PregSource: Crowdsourcing to Understand Pregnancy
|
||
Not yet recruiting |
NCT06336434 -
CREATE - Cabotegravir & Rilpivirine Antiretroviral Therapy in Pregnancy
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT05412238 -
Formulation and Evaluation of the Efficacy of Macro- and Micronutrient Sachets on Pregnant Mothers and Children Aged 6-60 Months
|
N/A | |
Not yet recruiting |
NCT04786587 -
Alcohol Self-reporting During Pregnancy. AUTOQUEST Study.
|
||
Not yet recruiting |
NCT05028387 -
Telemedicine Medical Abortion Service Using the "No-test" Protocol in Ukraine and Uzbekistan.
|
||
Completed |
NCT02683005 -
Study of Hepatitis C Treatment During Pregnancy
|
Phase 1 | |
Completed |
NCT02783170 -
Safety and Immunogenicity of Simultaneous Tdap and IIV in Pregnant Women
|
Phase 4 | |
Recruiting |
NCT02564250 -
Maternal Metabolism and Pregnancy Outcomes in Obese Pregnant Women
|
N/A | |
Recruiting |
NCT02507180 -
Safely Ruling Out Deep Vein Thrombosis in Pregnancy With the LEFt Clinical Decision Rule and D-Dimer
|
||
Recruiting |
NCT02619188 -
Nutritional Markers in Normal and Hyperemesis Pregnancies
|
N/A | |
Completed |
NCT02528136 -
The Clinical Carbetocin Myocardium Trial
|
Phase 4 |